Mercury reduces the enzymatic activity of neprilysin in differentiated SH-SY5Y cells

Toxicological Sciences

Volumn 145, Issue 1, 2015, Pages 128-137

  Chin Chan, Miguel ^a   Segovia, José ^b   Quintanar, Liliana ^b   Arcos López, Trinidad ^b   Hersh, Louis B ^c   Martin Chow, K ^c   Rodgers, David W ^c   Quintanilla Vega, Betzabet ^a  

^a Department of Toxicology ^*  (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Beta amyloid peptide; Lead; Mercury; Neprilysin; Retinoic acid

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; MERCURY; MESSENGER RNA;

ARTICLE; CELL DIFFERENTIATION; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME ACTIVITY; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SECRETION; HUMAN; METABOLISM; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; MERCURY; NEPRILYSIN;

EID: 84927642674     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfv037     Document Type: Article

References (47)

1. Alattia, J. R., Kuraishi, T., Dimitrov, M., Chang, I., Lemaitre, B., and Fraering, P. C. (2011). Mercury is a direct and potent gamma-secretase inhibitor affecting Notch processing and development in Drosophila. FASEB J. 25, 2287-2295.
2. Arima, J., Uesugi, Y., and Hatanaka, T. (2009). Bacillus D-stereospecific metallo-amidohydrolase: active-site metalion substitution changes substrate specificity. Biochimie 91, 568-576.
3. Armstrong, R. A. (1994). Differences in beta-amyloid (beta/A4) deposition in human patients with Down's syndrome and sporadic Alzheimer's disease. Neurosci. Lett. 169, 133-136.
4. Atwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N.M., Romano, D. M., Hartshorn, M. A., Tanzi, R. E., and Bush, A. I. (1998). Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273, 12817-12826.
5. Beckman, M., and Iverfeldt, K. (1997). Increased gene expression of beta-amyloid precursor protein and its homologues APLP1 and APLP2 in human neuroblastoma cells in response to retinoic acid. Neurosci. Lett. 221, 73-76.
6. Belyaev, N. D., Nalivaeva, N. N., Makova, N. Z., and Turner, A. J. (2009). Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep. 10, 94-100.
7. Clarkson, T.W., andMagos, L. (2006). The toxicology of mercury and its chemical compounds. Crit. Rev. Toxicol. 36, 609-662.
8. Culpan, D., Palmer, J., Miners, J. S., Love, S., and Kehoe, P. G. (2011). The influence of tumour necrosis factor-alpha (TNFalpha) on amyloid-beta (Abeta)-degrading enzymes in vitro. Int. J. Mol. Epidemiol. Genet. 2, 409-415.
9. Cheung, Y. T., Lau, W. K., Yu, M. S., Lai, C. S., Yeung, S. C., So, K. F., and Chang, R. C. (2009). Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 30, 127-135.
10. Dale, G. E., D'Arcy, B., Yuvaniyama, C., Wipf, B., Oefner, C., and D'Arcy, A. (2000). Purification and crystallization of the extracellular domain of human neutral endopeptidase (neprilysin) expressed in Pichia pastoris. Acta Crystallogr. D Biol. Crystallogr. 56, 894-897.
11. Duce, J. A., and Bush, A. I. (2010). Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics. Prog. Neurobiol. 92, 1-18.
12. El-Amouri, S. S., Zhu, H., Yu, J., Marr, R., Verma, I. M., and Kindy, M. S. (2008). Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am. J. Pathol. 172, 1342-1354.
13. Friberg, L., and Mottet, N. K. (1989). Accumulation of methylmercury and inorganic mercury in the brain. Biol. Trace Elem. Res. 21, 201-206.
14. Fujimura, M., Usuki, F., Sawada, M., and Takashima, A. (2009). Methylmercury induces neuropathological changes with tau hyperphosphorylation mainly through the activation of the c-jun-N-terminal kinase pathway in the cerebral cortex, but not in the hippocampus of the mouse brain. Neurotoxicology 30, 1000-1007.
15. Godfrey, M. E., Wojcik, D. P., and Krone, C. A. (2003). Apolipoprotein E genotyping as a potential biomarker for mercury neurotoxicity. J. Alzheimers Dis. 5, 189-195.
16. Grasso, G., Pietropaolo, A., Spoto, G., Pappalardo, G., Tundo, G. R., Ciaccio, C., Coletta, M., and Rizzarelli, E. (2011). Copper(I) and copper(II) inhibit Abeta peptides proteolysis by insulindegrading enzyme differently: implications for metallostasis alteration in Alzheimer's disease. Chemistry 17, 2752-2762.
17. Hardy, J. A., and Higgins, G. A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
18. Hock, C., Drasch, G., Golombowski, S., Muller-Spahn, F., Willershausen-Zonnchen, B., Schwarz, P., Hock, U., Growdon, J. H., and Nitsch, R. M. (1998). Increased blood mercury levels in patients with Alzheimer's disease. J. Neural Transm. 105, 59-68.
19. Holback, S., Adlerz, L., Gatsinzi, T., Jacobsen, K. T., and Iverfeldt, K. (2008). PI3-K-and PKC-dependent up-regulation of APP processing enzymes by retinoic acid. Biochem. Biophys. Res. Commun. 365, 298-303.
20. Huang, H., Bihaqi, S. W., Cui, L., and Zawia, N. H. (2011). In vitro Pb exposure disturbs the balance between Abeta production and elimination: the role of AbetaPP and neprilysin. Neurotoxicology 32, 300-306.
21. Hussain, S., Atkinson, A., Thompson, S. J., and Khan, A. T. (1999). Accumulation of mercury and its effect on antioxidant enzymes in brain, liver, and kidneys of mice. J. Environ. Sci. Health B 34, 645-660.
22. Iwata, N., Higuchi, M., and Saido, T. C. (2005). Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol. Ther. 108, 129-148.
23. Kim, D. K., Park, J. D., and Choi, B. S. (2014). Mercury-induced amyloid-beta (Abeta) accumulation in the brain is mediated by disruption of Abeta transport. J. Toxicol. Sci. 39, 625-635.
24. Leong, C. C., Syed, N. I., and Lorscheider, F. L. (2001). Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury. Neuroreport 12, 733-737.
25. Li, C., and Hersh, L. B. (1995). Neprilysin: assay methods, purification, and characterization. Methods Enzymol. 248, 253-263.
26. Li, X., Lv, Y., Yu, S., Zhao, H., and Yao, L. (2012). The effect of cadmium on Abeta levels in APP/PS1 transgenic mice. Exp. Ther. Med. 4, 125-130.
27. Liu, F., Xue, Z., Li, N., Huang, H., Ying, Y., Li, J., Wang, L., and Li, W. (2014). Effects of lead exposure on the expression of amyloid beta and phosphorylated tau proteins in the C57BL/6 mouse hippocampus at different life stages. J. Trace Elem. Med. Biol. 28, 227-232.
28. Miners, J. S., Baig, S., Tayler, H., Kehoe, P. G., and Love, S. (2009). Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J. Neuropathol. Exp. Neurol. 68, 902-914.
29. Mohajeri, M. H., Wollmer, M. A., and Nitsch, R. M. (2002). Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo. J. Biol. Chem. 277, 35460-35465.
30. Monnet-Tschudi, F., Zurich, M. G., Boschat, C., Corbaz, A., and Honegger, P. (2006). Involvement of environmental mercury and lead in the etiology of neurodegenerative diseases. Rev. Environ. Health 21, 105-117.
31. Mutter, J., Curth, A., Naumann, J., Deth, R., and Walach, H. (2010). Does inorganic mercury play a role in Alzheimer's disease? A systematic review and an integrated molecular mechanism. J. Alzheimers Dis. 22, 357-374.
32. Navarrete Santos, A., Wulfanger, J., Helbing, G., Blosz, T., Langner, J., and Riemann, D. (2002). Two C-terminal cysteines are necessary for proper folding of the peptidase neprilysin/ CD10. Biochem. Biophys. Res. Commun. 295, 423-427.
33. Olivieri, G., Brack, C., Muller-Spahn, F., Stahelin, H. B., Herrmann, M., Renard, P., Brockhaus, M., and Hock, C. (2000). Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J. Neurochem. 74, 231-236.
34. Petroni, D., Tsai, J., Agrawal, K., Mondal, D., and George, W. (2012). Low-dosemethylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells. Environ. Toxicol. 27, 549-555.
35. Rajanna, B., Chetty, C. S., Rajanna, S., Hall, E., Fail, S., and Yallapragada, P. R. (1995). Modulation of protein kinase C by heavy metals. Toxicol. Lett. 81, 197-203.
36. Shapiro, A. M., and Chan, H. M. (2008). Characterization of demethylation of methylmercury in cultured astrocytes. Chemosphere 74, 112-118.
37. Shinall, H., Song, E. S., and Hersh, L. B. (2005). Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. Biochemistry 44, 15345-15350.
38. Song, J. W., and Choi, B. S. (2013). Mercury induced the Accumulation of Amyloid Beta (Abeta) in PC12 Cells: the role of production and degradation of Abeta. Toxicol. Res. 29, 235-240.
39. Tai, H. C., and Lim, C. (2006). Computational studies of the coordination stereochemistry, bonding, and metal selectivity of mercury. J. Phys. Chem. A 110, 452-462.
40. Thinakaran, G., and Koo, E. H. (2008). Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283, 29615-29619.
41. Turner, A. J., Isaac, R. E., and Coates, D. (2001). The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23, 261-269.
42. Vahter, M. E., Mottet, N. K., Friberg, L. T., Lind, S. B., Charleston, J. S., and Burbacher, T. M. (1995). Demethylation of methyl mercury in different brain sites of Macaca fascicularis monkeys during long-term subclinical methyl mercury exposure. Toxicol. Appl. Pharmacol. 134, 273-284.
43. Wang, D. S., Lipton, R. B., Katz, M. J., Davies, P., Buschke, H., Kuslansky, G., Verghese, J., Younkin, S. G., Eckman, C., and Dickson, D. W. (2005). Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J. Neuropathol. Exp. Neurol. 64, 378-385.
44. Wenstrup, D., Ehmann, W. D., and Markesbery, W. R. (1990). Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains. Brain Res. 533, 125-131.
45. Wojcik, D. P., Godfrey, M. E., Christie, D., and Haley, B. E. (2006). Mercury toxicity presenting as chronic fatigue, memory impairment and depression: diagnosis, treatment, susceptibility, and outcomes in a New Zealand general practice setting (1994-2006). Neuro Endocrinol. Lett. 27, 415-423.
46. Wu, J., Basha, M. R., Brock, B., Cox, D. P., Cardozo-Pelaez, F., McPherson, C. A., Harry, J., Rice, D. C., Maloney, B., Chen, D., et al. (2008). Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J. Neurosci. 28, 3-9.
47. Yasojima, K., Akiyama, H., McGeer, E. G., and McGeer, P. L. (2001). Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett. 297, 97-100.